Redwood Pharma to present at BIO-Europe Spring

Redwood Pharma will present on March 24 in Paris, France, at BIO-Europe Spring, one of Europe's largest life science partnership conferences, where it will give an update on the business and discuss potential and business partnerships for RP101, the company's leading product under development.

Redwood Pharma is currently conducting a Phase II clinical trial of RP101 in Europe and has previously announced an intention to publish topline results by the end of March.

The presentation will be made by CEO Martin Vidaeus and Professor Gerhard Garhöfer of the Medical University of Vienna. Professor Garhöfer, a leading expert in ophthalmology in Europe with long experience in treating patients with dry eyes, is also the lead investigator in Redwood Pharma's Phase II clinical trial.

The presentation will take place at the Porte de Versailles Hall 7, Level 7.3 conference center room E04 on Tuesday March 24 at 11:00 CET. During the conference, Redwood Pharma will meet with interested parties offsite near the conference center and will also be scheduling meetings in the conference partnering system. To book a meeting, please do so via the BIO-Europe Spring’s online partnership platform at: partneringone.knect365.com, or contact:

Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.com

About RP101

RP101 is a novel, topical treatment for post-menopausal women suffering from chronic, moderate-to-severe dry eye disease (DED).  This Phase II product candidate consists of a low-dose estrogen analog formulated in IntelliGel, a proprietary controlled-release drug delivery platform, and will be the first hormonal therapy for DED targeted to specific underlying biological mechanisms in critical tissues in and around the eye.  Redwood Pharma initiated a randomized, placebo-controlled multicenter Phase II trial where the first patient was dosed in February 2019, with the last patient exiting the trial in November 2019 and topline results expected in Q1 2020. Highlights include:

• Serious unmet medical need (US$3bn global DED market) and well-defined addressable market – 7% of all post-menopausal women suffer from moderate-to-severe DED, 10m in the US & Europe alone
• Estrogen – a safe and effective API found in 500+ products sold globally. RP101 will deliver a topical, low dose to the eye
• Novel IntelliGel drug delivery platform well-suited for ophthalmic use – increases bioavailability, reduces number of doses
• Strong safety profile and efficacy data, including positive data from 2 previous Phase II trials in the US of 138 patients demonstrating safety profile and improvement of both signs and symptoms in post-menopausal women with moderate-to-severe DED
• Phase II data in Q1 2020, with GMP production established and clear path to commercialization
• Strong IP and market exclusivity

About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ.) is listed on the Spotlight Stock Market  (Ticker: REDW.ST, ISIN: SE008294789).

For more information visit: www.redwoodpharma.com